Company profile

Pavan Cheruvu
Fiscal year end
Former names
Axovant Gene Therapies Ltd., Axovant Sciences Ltd., Roivant Neurosciences Ltd.

SIOX stock data



13 Nov 20
16 Jan 21
31 Mar 21


Quarter (USD) Sep 20 Jun 20 Dec 19 Sep 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 20 Mar 19 Mar 18 Mar 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 63.17M 63.17M 63.17M 63.17M 63.17M 63.17M
Cash burn (monthly) (positive/no burn) 1.75M 3.38M 3.87M 3.94M 4.76M
Cash used (since last report) n/a 6.24M 12.05M 13.82M 14.06M 16.99M
Cash remaining n/a 56.93M 51.13M 49.35M 49.12M 46.18M
Runway (months of cash) n/a 32.5 15.1 12.7 12.5 9.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
24 Nov 20 Pande Atul Common Stock Buy Aquire P No 2.3399 10,000 23.4K 33,370
5 Oct 20 Vuori Kristiina MD Stock Option Common Stock Grant Aquire A No 5.63 35,000 197.05K 35,000
8 Jul 20 Cheruvu Pavan Common Shares Buy Aquire P No 2.737 37,500 102.64K 57,836
8 Jul 20 Pande Atul Common Shares Buy Aquire P No 2.729 10,000 27.29K 23,370
23.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 49 44 +11.4%
Opened positions 12 6 +100.0%
Closed positions 7 7
Increased positions 9 12 -25.0%
Reduced positions 14 8 +75.0%
13F shares
Current Prev Q Change
Total value 52.7M 33.66M +56.6%
Total shares 11.41M 11.94M -4.5%
Total puts 311.32K 137.02K +127.2%
Total calls 187.17K 81.57K +129.5%
Total put/call ratio 1.7 1.7 -1.0%
Largest owners
Shares Value Change
Consonance Capital Management 3.24M $14.95M -11.4%
Opaleye Management 2.04M $9.42M NEW
Hudson Bay Capital Management 1.33M $6.12M -20.9%
Sphera Funds Management 1.15M $5.33M -59.7%
Corriente Advisors 875K $4.04M NEW
Rubric Capital Management 460.2K $2.13M 0.0%
Renaissance Technologies 440.92K $2.04M -35.7%
Two Sigma Investments 308.32K $1.42M +495.0%
Susquehanna International 185.76K $858K +832.4%
Ikarian Capital 177.68K $820K -5.9%
Largest transactions
Shares Bought/sold Change
Opaleye Management 2.04M +2.04M NEW
Sphera Funds Management 1.15M -1.71M -59.7%
Corriente Advisors 875K +875K NEW
DAFNA Capital Management 171.08K -834.31K -83.0%
Citadel Advisors 62.44K -704.97K -91.9%
Consonance Capital Management 3.24M -416.97K -11.4%
Hudson Bay Capital Management 1.33M -350K -20.9%
Two Sigma Investments 308.32K +256.5K +495.0%
Renaissance Technologies 440.92K -245K -35.7%
BAC Bank Of America 175.16K +175.16K +8757800.0%

Financial report summary

  • We have a limited operating history and have never generated any product revenues.
  • Our business, operations and clinical development plans and timelines could be adversely impacted by the effects of health epidemics, including the recent COVID-19 pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturers, contract research organizations, or CROs, shippers and others.
  • We are in the process of implementing a business plan that may continue to evolve as we integrate our newly licensed gene therapy product candidates. Our business plan may lead to the initiation of one or more development programs, the discontinuation of one or more development programs, or the execution of one or more transactions that you do not agree with or that you do not perceive as favorable to your investment.
  • We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability. Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
  • We may not be successful in our efforts to identify and acquire additional gene therapy product candidates, or to enter into collaborations or strategic alliances for the development and commercialization of any such future product candidates.
  • We are heavily dependent on the success of our gene therapy product candidates, which are still in early stages of clinical or preclinical development. If we are unable to successfully develop and commercialize any of our product candidates, our business will be harmed.
  • We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.
  • Raising additional funds by issuing securities may cause dilution to existing shareholders, raising additional funds through debt financings may involve additional restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.
  • We may be required to make significant payments to third parties under the agreements pursuant to which we acquired our gene therapy product candidates.
  • We may not be able to manage our business effectively if we are unable to attract and retain key personnel. In addition, if we are unable to effectively transition and integrate our new executive officers, our business and financial performance could be adversely affected.
  • Our employees, independent contractors, principal investigators, consultants, commercial collaborators, manufacturers, service providers and other vendors, or those of our affiliates, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
  • Our business and operations would suffer in the event of system failures, security breaches or cyber-attacks.
  • Operation of our business internationally exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business in various jurisdictions globally.
  • Legal, political and economic uncertainty surrounding the planned exit of the United Kingdom ("U.K.") from the European Union ("EU") are a source of instability and uncertainty.
  • Brexit may adversely impact our ability to obtain regulatory approvals of our product candidates in the U.K. or the EU and may require us to incur additional expenses to develop and commercialize our product candidates in the U.K. or the EU or receive clinical supply of our product candidates from manufacturing partners in the U.K.
  • Use of social media platforms presents new risks.
  • The failure to maintain our current enterprise resource planning system ("ERP") could adversely impact our business and results of operations.
  • Potential product liability lawsuits against us could cause us to incur liabilities and limit commercialization of any products that we may develop.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • If we fail to comply with applicable U.S. and foreign privacy and data protection laws and regulations, we may be subject to liabilities that adversely affect our business, operations and financial performance.
  • Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome.
  • Interim "top-line" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
  • We face significant competition from other biotechnology and pharmaceutical companies, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours and our operating results will suffer if we fail to compete effectively.
  • If we are not able to obtain required regulatory approvals, we will not be able to commercialize our gene therapy product candidates, and our ability to generate revenue will be materially impaired.
  • Our gene therapy product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • Our AAV-based gene therapy product candidates and our lentiviral-based gene therapy product candidate are based on new gene transfer technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.
  • Even if we obtain FDA approval for our gene therapy product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.
  • Even if we obtain regulatory approval for our product candidates, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.
  • Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
  • Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Increasing demand for compassionate use or expanded access of our unapproved therapies could negatively affect our reputation and harm our business.
  • If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates, even if approved.
  • If the market opportunities for any product candidates we may develop are smaller than we believe they are, our revenues, if any, may be adversely affected, and our business may suffer. Because the target patient populations for many of the product candidates we may develop are small, we must be able to successfully identify patients and achieve a significant market share to achieve and maintain profitability and growth.
  • If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
  • Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell our products profitably, if approved.
  • Gene therapies are novel, complex and difficult to manufacture. We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our product candidates.
  • Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.
  • We intend to rely on third parties to conduct, supervise and monitor our nonclinical studies and our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.
  • We may seek to enter into collaborations in the future with other third parties. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected.
  • If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
  • If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term and obtain data exclusivity for our product candidates, our business may be materially harmed.
  • The validity, scope and enforceability of any patents that cover our biologic product candidates can be challenged by third parties.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • Third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights may delay or prevent the development and commercialization of our product candidates.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
  • If we breach any of our license or collaboration agreements, it could compromise our development and commercialization efforts for our product candidates.
  • Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.
  • We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.
  • Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world, which could impair our business.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • An active trading market for our common shares may not be sustained.
  • The market price of our common shares has been and is likely to continue to be highly volatile, and you may lose some or all of your investment.
  • Volatility in our share price could subject us to securities class action litigation.
  • We are no longer a "controlled company" within the meaning of the applicable rules of the Nasdaq and, as a result, no longer qualify for exemptions from certain corporate governance requirements. If we fail to meet the phase-in deadlines for these corporate governance requirements, our common stock could be delisted from the Nasdaq.
  • RSL owns a significant percentage of our common shares and is able to exert significant control over matters subject to shareholder approval.
  • Our organizational and ownership structure may create significant conflicts of interests.
  • If securities or industry analysts cease to publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.
  • Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.
  • Future sales of our common shares, or the perception that such sales may occur, could depress our share price, even if our business is doing well.
  • We have incurred and will continue to incur substantial costs as a result of operating as a public company, and our management has been and will be required to continue to devote substantial time to compliance with our public company responsibilities and corporate governance practices.
  • If we are unable to maintain proper and effective internal controls over financial reporting and disclosure controls and procedures, investor confidence in our company and, as a result, the value of our common shares, may be adversely affected.
  • We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common shares less attractive to investors.
  • We are a Bermuda company and it may be difficult for you to enforce judgments against us or our directors and executive officers.
  • Bermuda law differs from the laws in effect in the United States and may afford less protection to our shareholders.
  • There are regulatory limitations on the ownership and transfer of our common shares.
  • Our third amended and restated bye-laws enable our board of directors to issue preference shares, which may discourage a change of control.
  • We may become subject to unanticipated tax liabilities and higher effective tax rates.
  • The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our business.
  • Changes in our effective tax rate may reduce our net income in future periods.
  • U.S. persons that own 10% or more of the vote or value of our common shares ("U.S. shareholders") may suffer adverse tax and compliance consequences because we previously were (and may continue to be), and/or our non-U.S. subsidiaries are expected to be, characterized as a controlled foreign corporation ("CFC") under Section 957(a) of the U.S. Internal Revenue Code of 1986, as amended ("the Code").
  • U.S. holders of our common shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company ("PFIC").
  • Taxable gains or losses associated with the pre-funded warrants issued in February 2020 may arise, which depend on the market price of the common shares underlying the pre-funded warrants, and may subject us to future tax liabilities in the United Kingdom if they cannot be offset by our current or carried-forward losses in the United Kingdom, potentially harming our business, financial condition and results of operations.
Content analysis ?
H.S. junior Avg
New words: abatement, accrual, ADVISOR, ASEU, awaiting, background, Canada, Canadian, certificate, Chancery, complaint, consummation, contrary, conversion, cumulative, description, DGCL, dividend, doctrine, domestication, domiciled, duty, embedded, England, facially, fix, Floor, forum, frustrate, GMP, grandparent, Hedging, HHS, immaterial, inapplicable, indirect, inpatient, insulin, legislature, minimize, nurse, partner, radically, reorganization, rescinded, settlement, sio, SIOX, Square, stockholder, sublease, symbol, telephone, tender, text, tie, URGE, URGED, venue, vigorously, Viralgen, visit, washout
Removed: afford, appointed, bidder, centrally, CFC, complained, constituting, constructive, depositary, director, dishonesty, disposing, doubtful, Erosion, growing, indemnification, interested, mitigate, Nationwide, nominating, offered, oppressive, ordinarily, Organisation, permission, preference, preferential, prejudicial, premium, prevailing, Profit, proscribed, recommended, resident, selection, Shifting, sought, Subpart, takeover, tangible, waived